

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number  
**WO 02/088146 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 519/00**,  
491/04, A61K 31/407, A61P 25/00

(21) International Application Number: PCT/US02/13118

(22) International Filing Date: 25 April 2002 (25.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/286,575 26 April 2001 (26.04.2001) US

(71) Applicant: **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: **STACK, Gary, Paul**; 525 Brookfield Lane, Ambler, PA 19002 (US). **TRAN, Megan**; Apt. 3G, 82 Clinton Street, Hoboken, NJ 07030 (US). **BRAVO, Byron, Abel**; Apartment H11, 201 Chariot Lane, Eagleville, PA 19403 (US).

(74) Agents: **BARRETT, Rebecca, R.**; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 02/088146 A2**

(54) Title: ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOX-INO[2,3-e]INDOLE

(57) Abstract: Compounds of the formula (I) are useful in the treatment of central nervous system disorders including depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders and addictive disorders caused by ethanol or cocaine abuse.

**ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF**  
**2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE**

5 This invention relates to antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole, to processes for preparing them; methods of using them and to pharmaceutical compositions containing them.

**Background of the Invention**

10 Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.

15 Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the most prescribed drugs. They nonetheless have a slow onset of action, often taking several weeks to produce their full therapeutic effect. Furthermore, they are effective in fewer than two-thirds of patients.

20 Serotonin selective reuptake inhibitors (SSRIs) are well known for the treatment of depression and other conditions. SSRIs work by blocking the neuronal reuptake of serotonin, thereby increasing the concentration of serotonin in the synaptic space, and thus increasing the activation of postsynaptic serotonin receptors.

25 However, although a single dose of an SSRI can inhibit the neuronal serotonin transporter which would be expected to increase synaptic serotonin, long-term treatment is required before clinical improvement is achieved.

30 It has been suggested that the SSRIs increase the serotonin levels in the vicinity of the serotonergic cell bodies and that the excess serotonin activates somatodendritic autoreceptors, 5-HT<sub>1A</sub> receptors, causing a decrease in serotonin release in major forebrain areas. This negative feedback limits the increment of synaptic serotonin that can be induced by antidepressants.


35 A 5-HT<sub>1A</sub> antagonist would limit the negative feedback and should improve the efficacy of the serotonin reuptake mechanism. (Perez, V., et al., *The Lancet*,

349:1594-1597 (1997)). Such a combination therapy would be expected to speed up the effect of the serotonin reuptake inhibitor.

Thus, it is highly desirable to provide improved compounds which both inhibit  
5 serotonin reuptake and which are antagonists of the 5-HT<sub>1A</sub> receptor.

### Description of the Invention

In accordance with this invention, there is provided a group of novel  
10 compounds of the formula:



I

wherein

15 R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

20 R<sup>2</sup> is hydrogen, halogen, alkyl of 1 to 6 carbon atoms or trifluoromethyl;

R<sup>6</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;

Z is CR<sup>7</sup> or N;

and pharmaceutically acceptable salts thereof.

25 In some preferred embodiments of the invention R<sup>1</sup> is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms. In still more preferred embodiments of the invention R<sup>1</sup> is hydrogen or alkyl of 1 to 6 carbon atoms. R<sup>1</sup> is still more preferably hydrogen.

In other embodiments of the invention  $R^2$  is hydrogen, trifluoromethyl, or alkyl of one to six carbon atoms. In still more preferred embodiments of the present invention,  $R^2$  is hydrogen or lower alkyl.

5         $R^3$ ,  $R^4$  and  $R^5$  are independently selected from hydrogen, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, and alkoxy of 1 to 6 carbon atoms in some embodiments of the invention. More preferably  $R^3$ ,  $R^4$  and  $R^5$  are independently selected from halogen, cyano and hydrogen. Still more preferably,  $R^3$ ,  $R^4$  and  $R^5$  are independently selected from halogen and hydrogen.

10

Where Z is  $CR^7$ ,  $R^7$  is preferably hydrogen, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms, more preferably  $R^7$  is halogen, cyano or hydrogen. Still more preferably  $R^7$  is halogen or hydrogen.

15

$R^6$  is preferably hydrogen or lower alkyl.

Most preferred are compounds where  $R^1$  is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms,  $R^2$  is hydrogen, trifluoromethyl or alkyl of 1 to 6 carbon atoms,  $R^3$ ,  $R^4$  and  $R^5$  are  
20 independently selected from hydrogen, halo and cyano and  $R^6$  is hydrogen.

Still more preferred compounds of the present invention are compounds where  $R^1$  is hydrogen,  $R^2$  is hydrogen or lower alkyl,  $R^3$ ,  $R^4$  and  $R^5$  are independently selected from hydrogen and halogen, Z is  $CR^7$ ,  $R^6$  is hydrogen, and  $R^7$  is hydrogen  
25 or halogen.

This invention relates to both the R and S stereoisomers of the 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole derivatives as well as to mixtures of the R and S stereoisomers. Throughout this application, the name of the product of this invention,  
30 where the absolute configuration of the 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole derivative is not indicated, is intended to embrace the individual R and S enantiomers

as well as mixtures of the two. In some preferred embodiments of the present invention the S stereoisomer is preferred.

Where a stereoisomer is preferred, it may in some embodiments, be provided  
5 substantially free of the corresponding enantiomer. Thus, an enantiomer substantially free of the corresponding enantiomer refers to a compound which is isolated or separated via separation techniques or prepared free of the corresponding enantiomer. Substantially free, as used herein means that the compound is made up of a significantly greater proportion of one stereoisomer. In preferred embodiments  
10 the compound is made up of at least about 90% by weight of a preferred stereoisomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of a preferred stereoisomer. Preferred stereoisomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and  
15 crystallization of chiral salts or by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre  
20 Dame Press, Notre Dame, IN 1972).

Alkyl as used herein refers to an aliphatic hydrocarbon chain and includes straight and branched chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl.  
25 Lower alkyl refers to alkyl having 1 to 3 carbon atoms.

Alkanamido as used herein refers to the group  $R-C(=O)-NH-$  where R is an alkyl group of 1 to 5 carbon atoms.

Alkanoyloxy as used herein refers to the group  $R-C(=O)-O-$  where R is an alkyl group of 1 to 5 carbon atoms.

30 Alkanesulfonamido as used herein refers to the group  $R-S(O)_2-NH-$  where R is an alkyl group of 1 to 6 carbon atoms.

Alkoxy as used herein refers to the group  $R-O-$  where R is an alkyl group of 1 to 6 carbon atoms.

Carboxamido as used herein refers to the group  $-CO-NH_2$ .

Carboalkoxy as used herein refers to the group R-O-C(=O)- where R is an alkyl group of 1 to 5 carbon atoms.

Halogen (or halo) as used herein refers to chlorine, bromine, fluorine and iodine.

5 Pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known acceptable acids.

10

Specific examples of the present invention include:

2-[(4-(1H-Indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-8-methyl-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole;

2-[(4-(1H-Indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole;

15

2-[(4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole;


8-ethyl-2-[(4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)nyl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,7-e]indole; and

20

8-ethyl-2-[(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,7-e]indole.

Accordingly in a further aspect this invention provides processes for preparing the compounds of formula (I) which processes comprise one of the following:


25 a) reacting a compound of formula



(II)

wherein R<sup>1</sup> and R<sup>2</sup> are as defined herein and X is a leaving group, e.g. a halogen or an organic sulphonyloxy group, such as methane- or toluene-, with a compound of formula (III):

30



wherein Z, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined herein to give a compound of formula (I);

or

- 5 (b) converting a basic compound of formula (I) to a pharmaceutically acceptable acid addition salt thereof;


or

- (c) resolving an isomeric mixture of compounds of formula (I) to isolate an enantiomer of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
- 10

Where necessary in the reactions described herein reactive substituent groups/sites may be protected before the reaction and removed thereafter.

- 15 The 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indoles of Formula I are prepared as illustrated below. Specifically, the appropriately substituted nitroguaiacol (1) is alkylated with allyl bromide in the presence of a suitable base such as sodium hydride to produce (2) and then demethylated by a reagent such as sodium hydroxide. The resulting 4-nitro-2-allyloxyphenol (3) is then alkylated with glycidyl tosylate or an
- 20 epihalohydrin in the presence of a base such as sodium hydride to produce (4) and heated in a high boiling solvent such as mesitylene or xylene to effect both Claisen rearrangement of the allyl group and cyclization of the dioxan ring. The resulting primary alcohol (5) is converted to the tosylate (6) by reaction with p-toluenesulfonyl chloride in the presence of a tertiary amine or pyridine, or alternatively to a halide by
- 25 reaction with carbon tetrabromide or carbon tetrachloride in combination with triphenylphosphine. The allyl side chain is then cleaved to the aldehyde (7) by treatment with ozone at low temperature, followed by work-up with a tertiary base such as diisopropylethylamine or triethylamine, or by treatment with catalytic osmium tetroxide and sodium periodate. Reduction of the nitro group with hydrogen over
- 30 platinum oxide leads directly to formation of the indole (8) in which R<sup>2</sup> is hydrogen.

Alternatively, the aldehyde may be treated with an appropriate alkyl Grignard reagent or with trifluoromethyl trimethylsilane in the presence of cesium fluoride, then oxidized




Scheme I

to a ketone with a suitable oxidant such as pyridinium chlorochromate (PCC) or the Swern reagent and reduced with hydrogen over platinum oxide to give the indoles in which R<sup>2</sup> is alkyl or trifluoromethyl. Replacement of the tosylate or halide with the



appropriately substituted indoletetrahydropyridine in some high boiling solvent such as dimethyl sulfoxide gives the title compounds of the invention.

- 5 The compounds of the invention in which R<sup>2</sup> is a halogen such as chlorine or bromine are prepared from the nitroaldehyde (7) described above by the procedure of Scheme II. The aldehyde is oxidized to the phenylacetic acid (10) by a suitable oxidant such as the Jones reagent (CrO<sub>3</sub>, H<sub>2</sub>SO<sub>4</sub> in acetone) and then the nitro group is reduced to the amine (11) by treatment with hydrogen in the presence of a catalyst such as palladium on carbon. Cyclization to the oxindole is effected by treatment with acid and the oxindole converted to the
- 10 acid and the oxindole converted to the




Scheme II

- haloindole such as bromo or chloroindole via treatment with the appropriate carbon tetrahalide and triphenylphosphine in a solvent such as methylene chloride. Replacement of the tosylate with the appropriately substituted indole-tetrahydropyridine in some high boiling solvent such as dimethyl sulfoxide gives the title compounds of the invention.
- 15

- 20 The compounds of the invention may alternatively be prepared from the 7-nitro-8-allyl benzodioxan derived from the Claisen rearrangement by the procedure of Scheme III. The alcohol is converted to the tosylate or halide (6) as described above and the double bond is isomerized by treatment with bis-acetonitrile palladium (II)


- chloride in refluxing methylene chloride or benzene. Cleavage of the olefin with ozone or osmium tetroxide/periodate gives the o-nitrobenzaldehyde (12), which is condensed with the appropriate nitroalkane in the presence of a suitable base catalyst to yield the corresponding o, $\beta$ -dinitrostyrene (13). Reduction of both nitro groups with hydrogen over palladium on carbon is accompanied by cyclization to form the indole (8). Replacement of the tosylate with the appropriately substituted indoletetrahydro-pyridine as above gives the title compounds of the invention.



Scheme III

- The o-nitrobenzaldehyde used in the condensation described above may be alternatively prepared as shown in Scheme IV. The appropriate mono-allylated catechol (14) is elaborated with glycidyl tosylate as described above (15) and rearranged in refluxing mesitylene. Cyclization to the benzodioxan methanol (16) is effected by treatment with sodium bicarbonate in ethanol and the alcohol is converted to the tosylate or halide (17) as described above. After rearrangement of the double

bond by treatment with catalytic bis-acetonitrile palladium (II) chloride in refluxing methylene chloride and cleavage with ozone or osmium tetroxide and




Scheme IV

5

sodium periodate as described above, the resulting aldehyde (18) is regioselectively nitrated with a combination of nitric acid and tin (IV) chloride to produce (12).

Compounds of the invention in which R<sup>2</sup> is methyl may be most conveniently prepared from the 7-nitro-8-allyl benzodioxan (6) described above by the procedure of Scheme V. The nitro group is

10



Scheme V

reduced with tin (II) chloride dihydrate in refluxing ethyl acetate to produce (19) and cyclization to the 2-methylindole (8a) effected by several days' treatment with catalytic

5 bis-acetonitrile (II) chloride, lithium chloride and 1,4-benzoquinone at room temperature in tetrahydrofuran. Replacement of the tosylate with the appropriately substituted indoletetrahydropyridine as above gives the title compounds of the invention

10 The guaiacols, catechols and indoletetrahydropyridines appropriate to the above chemistry are known compounds or can be prepared by one skilled in the art. The compounds of the invention may be resolved into their enantiomers by conventional methods or, preferably, the individual enantiomers may be prepared directly by substitution of (2R)-(-)-glycidyl 3-nitrobenzenesulfonate or tosylate (for the

15 S benzodioxan methanamine) or (2S)-(+)-glycidyl 3-nitrobenzenesulfonate or tosylate (for the R enantiomer) in place of epihalohydrin or racemic glycidyl tosylate in the procedures above.

A protocol similar to that used by Cheetham et. al. (Neuropharmacol. 32:737, 20 1993) was used to determine the affinity of the compounds of the invention for the serotonin transporter. The compound's ability to displace <sup>3</sup>H-paroxetine from male rat frontal cortical membranes was determined using a Tom Tech filtration device to

separate bound from free  $^3\text{H}$ -paroxetine and a Wallac 1205 Beta Plate<sup>®</sup> counter to quantitate bound radioactivity.  $K_i$ 's thus determined for standard clinical antidepressants are 1.96 nM for fluoxetine, 14.2 nM for imipramine and 67.6 nM for zimelidine. A strong correlation has been found between  $^3\text{H}$ -paroxetine binding in rat  
5 frontal cortex and  $^3\text{H}$ -serotonin uptake inhibition.

High affinity for the serotonin 5-HT<sub>1A</sub> receptor was established by testing the claimed compound's ability to displace [ $^3\text{H}$ ] 8-OHDPAT (dipropylaminotetralin) from the 5-HT<sub>1A</sub> serotonin receptor following a modification of the procedure of Hall et al., J.  
10 Neurochem. 44, 1685 (1985) which utilizes CHO cells stably transfected with human 5-HT<sub>1A</sub> receptors. The 5-HT<sub>1A</sub> affinities for the compounds of the invention are reported below as  $K_i$ 's.

Antagonist activity at 5-HT<sub>1A</sub> receptors was established by using a  $^{35}\text{S}$ -GTP $\gamma$ S  
15 binding assay similar to that used by Lazareno and Birdsall (Br. J. Pharmacol. 109: 1120, 1993), in which the test compound's ability to affect the binding of  $^{35}\text{S}$ -GTP $\gamma$ S to membranes containing cloned human 5-HT<sub>1A</sub> receptors was determined. Agonists produce an increase in binding whereas antagonists produce no increase but rather reverse the effects of the standard agonist 8-OHDPAT. The test compound's  
20 maximum inhibitory effect is represented as the  $I_{\text{max}}$ , while its potency is defined by the  $\text{IC}_{50}$ .

The results of the three standard experimental test procedures described in the preceding three paragraphs were as follows:

25

Compound	5-HT Transporter Affinity	5-HT <sub>1A</sub> Receptor Affinity	5-HT <sub>1A</sub> Function
	$K_i$ (nM)	$K_i$ (nM)	$\text{IC}_{50}$ (nM) ( $I_{\text{max}}$ )
Example 1	3.44	0.45	16.0 (100)
Example 2	0.77	1.55	23.0 (52)
30 Example 3	1.23	2.45	11.3 (100)
Example 4	10.00	4.56	73.0 (78)
Example 5	10.00	26.34	265.5 (98)

Like the antidepressants fluoxetine, paroxetine and sertraline, the compounds of this invention have the ability to potently block the reuptake of the brain neurotransmitter serotonin. They are thus useful for the treatment of depression and other diseases commonly treated by the administration of serotonin selective reuptake inhibitor (SSRI) antidepressants. Moreover, the compounds of this invention have potent affinity for and antagonist activity at brain 5-HT<sub>1A</sub> serotonin receptors. Recent clinical trials employing drug mixtures (eg, fluoxetine and pindolol) have demonstrated a more rapid onset of antidepressant efficacy for a treatment combining SSRI activity and 5-HT<sub>1A</sub> antagonism (Blier and Bergeron, 1995; F. Artigas et. al., 1996; M. B. Tome et. al., 1997). The compounds of the invention are thus exceedingly interesting and useful for treating depressive illnesses.

Hence, the compounds of this invention are combined serotonin reuptake inhibitors/5-HT<sub>1A</sub> antagonists and are useful for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor, such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction (including premature ejaculation), and related illnesses.

Thus the present invention provides methods of treating, preventing, inhibiting or alleviating each of the maladies listed above in a mammal, preferably in a human, the methods comprising providing a pharmaceutically effective amount of a compound of this invention to the mammal in need thereof.

Also encompassed by the present invention are pharmaceutical compositions for treating or controlling disease states or conditions of the central nervous system comprising at least one compound of Formula I, mixtures thereof, and or pharmaceutical salts thereof, and a pharmaceutically acceptable carrier therefore. Such compositions are prepared in accordance with acceptable pharmaceutical

procedures, such as described in *Remingtons Pharmaceutical Sciences*, 17th edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA (1985). Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.

5

The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

5

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

15 The amount provided to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, and the state of the patient, the manner of administration, and the like. In therapeutic applications, compounds of the present invention are provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate  
20 the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective amount." The dosage to be used in the treatment of a specific case must be subjectively determined by the attending physician. The variables involved include the specific condition and the size, age and response pattern of the patient. Generally, a starting dose is about 5  
25 mg per day with gradual increase in the daily dose to about 150 mg per day, to provide the desired dosage level in the human.

Provide, as used herein, means either directly administering a compound or composition of the present invention, or administering a prodrug, derivative or analog  
30 which will form an equivalent amount of the active compound or substance within the body.

The present invention includes prodrugs of compounds of Formula I. "Prodrug", as used herein means a compound which is convertible *in vivo* by metabolic means



(e.g. by hydrolysis) to a compound of Formula I. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, 5 Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992), Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975).

10 The following examples illustrate the production of representative compounds of this invention.

#### INTERMEDIATE 1

##### 3-Allyloxy-4-methoxynitrobenzene

15

97.5 g (0.51 mole) of the sodium salt of 5-nitroguaiacol was dissolved in one liter of N,N-dimethylformamide and 1.5 equivalents of allyl bromide added. The reaction was heated to 65°C for two hours, after which time much of the dark color had discharged and tlc (1:1 methylene chloride/hexane) indicated loss of starting 20 material. The solvent was concentrated in vacuum and the residue washed with water. The product was isolated by filtration and dried in a vacuum. This gave 112 g of pale yellow solid. A sample recrystallized from methanol gave m.p. 93-94°C.

25

#### INTERMEDIATE 2

##### 2-Allyloxy-4-nitrophenol

To one liter of dimethyl sulfoxide was added 750 mL of 2 N aqueous sodium hydroxide and the mixture was heated to 65°C. The pale yellow solid 3-allyloxy-4- 30 methoxynitrobenzene prepared above was added in portions over a 30 minute period and then the temperature was raised to 95°C and maintained for 3 hours, after which time the starting material had been consumed. The mixture was allowed to cool and poured into a mixture of 1 L ice and 1 L 2 N HCl. 73 Grams of crude but homogeneous (by tlc 1:1 methylene chloride/hexane) desired product was isolated as 35 a light brown solid by filtration. This material was subsequently dissolved in 1:1

- hexane/methylene chloride and filtered through silica gel to give 68 g of pale yellow solid, which, when recrystallized from ethyl/acetate/hexane, gave m.p. 61-62°C. The aqueous mother liquors from the initial crystallization above were extracted with 2 L of ethyl acetate. This was dried over sodium sulfate, filtered and evaporated to a dark oil. Column chromatography on silica with 1:1 methylene chloride/hexane gave an additional 12 g of the title compound as a yellow solid. Elution with 2% methanol in chloroform gave 12 g of a dark oil which slowly crystallized in vacuum. This proved to be the Claisen product, 3-allyl-4-nitrocatechol.

10

**INTERMEDIATE 3****2-(2-Allyloxy-4-nitrophenoxyethyl)-oxirane**

- 20 g (0.50 mole) of 60% NaH/mineral oil was placed in a two liter flask and washed with 500 mL of hexane. 1 L of N,N-dimethylformamide was added, followed by 77 g (0.40 mole) of the 2-allyloxy-4-nitrophenol prepared in the previous step. Addition of the phenol was performed in portions under argon. After stirring the mixture for 30 minutes at room temperature under argon, 108 g (0.48 moles) of (R)-glycidyl tosylate was added and the mixture heated at 70-75°C under nitrogen overnight. Upon cooling, the solvent was removed in vacuum and replaced with one liter of methylene chloride. This was washed with 500 mL portions of 2 N HCl (aq), saturated aqueous sodium bicarbonate and saturated brine and dried over sodium sulfate. The mixture was filtered, concentrated to an oil in vacuum and column chromatographed on silica gel using 1:1 hexane/methylene chloride as eluant. This gave 43 g of product contaminated with traces of the two starting materials, followed by 21 g of pure product as a pale yellow solid. The impure material was recrystallized from 1.2 L of 10% ethyl acetate/hexane to give 34 g of pure (homogeneous on silica gel tlc with 1:1 hexane/methylene chloride) (R)-2-(2-allyloxy-4-nitrophenoxyethyl)-oxirane (m.p. 64 °C).

Elemental Analysis for: C<sub>12</sub>H<sub>13</sub>NO<sub>5</sub>

30 Calc'd: C, 57.37; H, 5.21; N, 5.58

Found: C, 57.50; H, 5.21; N, 5.43

**INTERMEDIATE 4****(8-Allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-methanol**

(R)-2-(2-Allyloxy-4-nitrophenoxy-methyl)-oxirane (20 g, 80 mmoles) prepared as above was heated at 155°C in mesitylene for 24 hours under nitrogen. Filtration of the black solid which formed gave 1.5 g of very polar material. Evaporation of the solvent in vacuum followed by column chromatography on silica gel with methylene chloride as eluant gave 10 g of recovered starting material and 7.5 g of the desired rearranged (S)-(8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-methanol, which slowly crystallized on standing in vacuum (m.p. 67°C). The yield based on recovered starting material is 75%.

Elemental Analysis for: C<sub>12</sub>H<sub>13</sub>NO<sub>5</sub>

Calc'd: C, 57.37; H, 5.21; N, 5.58

Found: C, 57.26; H, 5.20; N, 5.35

**INTERMEDIATE 5****Toluene-4-sulfonic acid 8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-ylmethyl ester**

9.55 g (38.0 mmole) of (S)-(8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-yl)-methanol was dissolved in 465 mL of pyridine, 29.0 g (152 mmole) of p-toluenesulfonyl chloride was added and the mixture stirred at room temperature under nitrogen overnight. Water was then added to quench the excess tosyl chloride and the solvent was removed in vacuum and replaced with methylene chloride. This solution was washed with 2 N HCl (aq), with saturated aqueous sodium bicarbonate, and with saturated brine, and dried over magnesium sulfate. Filtration, evaporation in vacuum and column chromatography on silica gel with 1:1 hexane/methylene chloride as eluant gave 12.6 g (92%) of toluene-4-sulfonic acid (R)-allyl-7-nitro-2,3-benzo(1,4)dioxin-2-ylmethyl ester, which slowly crystallized to a tan solid (m.p. 60-62°C) upon standing.

Elemental Analysis for: C<sub>19</sub>H<sub>19</sub>NO<sub>7</sub>S

Calc'd: C, 56.29; H, 4.72; N, 3.45

Found: C, 56.13; H, 4.58; N, 3.44

**INTERMEDIATE 6****[8-Allyl-7-amino-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate**

5  
10  
15  
20  
(2R)-Toluene-4-sulfonic acid 8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-ylmethyl ester (5.3 g, 13 mmole) and tin (II) chloride dihydrate (14.7 g, 65 mmole) were combined in 500 mL of ethyl acetate and the mixture refluxed for 3 hours under nitrogen. The reaction was allowed to cool to room temperature and was quenched by the addition of 300 mL of saturated aqueous sodium bicarbonate. The biphasic mixture was filtered through celite, the phases separated and the aqueous back-extracted with 200 mL of ethyl acetate. The combined organic phases were washed with 250 mL portions of water and saturated brine, dried over sodium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with methylene chloride as eluant to give 2.2 g of the (R)-enantiomer of the title compound as an orange oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): doublet 7.8 δ (2 H); doublet 7.35 δ (2 H); doublet 6.6 δ (1 H); doublet 6.25 δ (1 H); multiplet 5.8 δ (1 H); singlet 5.05 δ (1 H); doublet 5.0 δ (1 H); multiplet 4.4 δ (1 H); multiplet 4.2 δ (3 H); doublet of doublets 4.0 δ (1 H); doublet 3.25 δ (2 H); singlet 2.45 δ (3 H).

**INTERMEDIATE 7****[8-Methyl-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol-2-yl]methyl 4-methylbenzenesulfonate**

25  
30  
Bis-acetonitrile (II) chloride (0.153 g, 0.60 mmole), 1,4-benzoquinone (0.64 g, 6.0 mmole) and lithium chloride (2.5 g, 60 mmole) were combined in 85 mL of tetrahydrofuran and the mixture stirred under argon for 5 minutes. A solution of (2R)-[8-allyl-7-amino-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzene-sulfonate (2.2 g, 5.9 mmole) in 25 mL of tetrahydrofuran was added and the mixture stirred for 48 hours at room temperature. The mixture was then diluted with 300 mL of ethyl acetate and washed with 200 mL portions of 1 N aqueous HCl, saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated in vacuum. Column chromatography on silica gel with methylene chloride as eluant gave 1.1 g of the (R)-enantiomer of the title compound as a gray

foam. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): doublet 7.8 δ (2 H); broad singlet 7.75 δ (1 H); doublet 7.3 δ (2 H); doublet 6.75 δ (1 H); doublet 6.63 δ (1 H); singlet 6.1 δ (1 H); multiplet 4.5 δ (1 H); multiplet 4.25 δ (3 H); doublet of doublets 4.07 δ (1 H); singlet 2.43 δ (3 H); singlet 2.40 δ (3 H).

5

### EXAMPLE 1

#### 2-[(4-(1H-Indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-8-methyl-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole

10 A solution of 0.55 g (1.5 mmole) of [(2R)-8-methyl-2,3-dihydro-7H-[1,4]-dioxino[2,3-e]indol-2-yl)methyl 4-methylbenzenesulfonate and 0.50 g (2.5 mmole) of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole in 6.0 mL of DMSO was heated at 65-7°C for 4 hours. The mixture was diluted with 300 mL of ethyl acetate, washed with 200 ml portions of saturated aqueous sodium bicarbonate and saturated brine, dried over  
15 magnesium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with 1% methanol in chloroform as eluant to give 0.21 g of the (S)-enantiomer of the title compound as a yellow solid, m.p. 212-215°C.

Elemental Analysis for: C<sub>25</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> • 0.50 H<sub>2</sub>O

Calc'd: C, 73.51; H, 6.42; N, 10.29

20 Found: C, 73.64; H, 6.31; N, 10.28

### INTERMEDIATE 8

#### [7-Nitro-8-(2-oxoethyl)-2,3-dihydro-1,4-benzodioxin-2-yl)methyl 4-methylbenzenesulfonate

25

A solution of 4.2 g (10 mmole) of toluene-4-sulfonic acid (2R)-8-allyl-7-nitro-2,3-dihydro-benzo(1,4)dioxin-2-ylmethyl ester in 400 mL of methylene chloride was cooled in a dry ice/isopropanol bath and saturated with ozone. It was then purged with oxygen and 2.6 g (20 mmole) of diisopropylethylamine added. The mixture was  
30 allowed to come to room temperature and stirred under nitrogen for 24 hours. It was then washed with 300 mL portions of 2 N HCl (aq), water and saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuum to give 3.8 g of the (R)-

enantiomer of the title compound as a white solid one-quarter hydrate, m.p. 116-120 °C.

Elemental Analysis for:  $C_{18}H_{17}NO_8S \cdot 0.25 H_2O$

Calc'd: C, 52.49; H, 4.28; N, 3.40

5 Found: C, 52.33; H, 3.92; N, 3.36

#### INTERMEDIATE 9

##### 2,3-Dihydro-7H-[1,4]dioxino[2,3-e]indol-2-ylmethyl 4-methylbenzenesulfonate

10 A mixture of 3.75 g (9.2 mmole) of [(2R)-7-nitro-8-(2-oxoethyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate and 3.0 g of platinum oxide in 50 mL of ethyl acetate was treated with 45 psi of hydrogen on a Parr hydrogenation apparatus for 6 hours. The mixture was then filtered through celite and concentrated in vacuum. The residue was column chromatographed on silica gel with first 10%  
15 hexane/methylene chloride, then 1% methanol/methylene chloride and finally 2% methanol/methylene chloride to give 1.50 g of the (R)-enantiomer of the title compound as a white solid one-quarter hydrate, m.p. 145°C.

Elemental Analysis for:  $C_{18}H_{17}NO_5S \cdot 0.25 H_2O$

Calc'd: C, 59.41; H, 4.85; N, 3.85

20 Found: C, 59.41; H, 4.57; N, 3.72

#### EXAMPLE 2

##### 2-[(4-(1H-Indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole

25 A solution of 0.65 g (1.8 mmole) of (2R)-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol-2-ylmethyl 4-methylbenzenesulfonate and 0.71 g (3.6 mmole) of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole in 30 mL of DMSO was heated at 65°C for 4 hours. The mixture was diluted with 300 mL of ethyl acetate, washed with 200 ml portions of  
30 saturated aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with 2-4% methanol in methylene chloride as eluant. The product fractions were combined and concentrated in vacuum, and the residue triturated with methylene chloride/hexane (1:1) to give 0.39 g of the (S)-enantiomer of

the title compound as a yellow solid, m.p. 126 °C, which retains one equivalent of DMSO.

Elemental Analysis for:  $C_{24}H_{23}N_3O_2 \cdot 0.25 H_2O \cdot C_2H_6OS$

Calc'd: C, 66.71; H, 6.35; N, 8.98

5 Found: C, 66.85; H, 6.18; N, 8.77

### EXAMPLE 3

#### 2-{[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl}-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole

10

A solution of 0.30 g (0.84 mmole) of (2R)-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol-2-ylmethyl 4-methylbenzenesulfonate and 0.40 g (1.8 mmole) of 5-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole in 30 mL of DMSO was heated at 65°C for 4 hours. The mixture was diluted with 300 mL of ethyl acetate, washed with 200 ml portions of saturated aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with 0-1.5% methanol in methylene chloride as eluant. The product fractions were combined and concentrated in vacuum, and the residue triturated with ether/hexane (1:1) to give 0.10 g of the (S)-enantiomer of the title compound as a yellow solid, m.p. 112°C, with one-quarter mole of ether.

15

20

Elemental Analysis for:  $C_{24}H_{22}FN_3O_2 \cdot 0.25 C_4H_{10}O$

Calc'd: C, 71.16; H, 5.85; N, 9.96

Found: C, 71.10; H, 5.42; N, 9.77

25

### INTERMEDIATE 10

#### {7-Nitro-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl}methyl 4-methylbenzenesulfonate

30

To a solution of 10.0 g (24.0 mmole) of (R)-[8-allyl-7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate in 700 mL of benzene was added 1.03 g of bis(acetonitrile)dichloropalladium (II) and the mixture was refluxed under nitrogen for 48 hours. The catalyst was then removed by filtration and the filtrate concentrated in vacuum to a brown oil. Column chromatography on silica gel with methylene chloride as eluant gave 7.2 g of the title compound as a mixture of E and Z

isomers. A sample of {(2R)-7-nitro-8[(E)-1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl)methyl 4-methylbenzenesulfonate was obtained as a yellow solid (m.p. 105-106 °C) by evaporation of a pure E isomer-containing fraction.

Elemental Analysis for: C<sub>19</sub>H<sub>19</sub>NO<sub>7</sub>S

5 Calc'd: C, 56.29; H, 4.72; N, 3.45

Found: C, 56.12; H, 4.64; N, 3.39

#### INTERMEDIATE 11

##### (8-Formyl-7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl 4-methylbenzenesulfonate

10

{(2R)-7-Nitro-8-[1-propenyl]-2,3-dihydro-1,4-benzodioxin-2-yl)methyl 4-methylbenzenesulfonate (10.5 g, 25.9 mmole) dissolved in 400 mL of methylene chloride was treated with excess ozone at -78°C. Diisopropylethylamine (11.5 mL, 66.0 mmole) was then added dropwise over 30 min and the mixture allowed to come to room temperature and stir overnight under a nitrogen atmosphere. The mixture was then diluted to 600 mL with methylene chloride, washed three times with 100 mL portions of 2N HCl (aq), twice with 200 mL portions of saturated aqueous sodium bicarbonate and with 200 mL of saturated brine. The solution was dried over magnesium sulfate, filtered and concentrated in vacuum to a crude brown oil, which was column chromatographed on silica gel with 10% hexane/methylene chloride to give 7.52 g of the (R)-enantiomer of the title compound as a yellow solid. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): doublet 7.8 δ (2 H); doublet 7.62 δ (1 H); doublet 7.4 δ (2 H); doublet 7.0 δ (1 H); multiplet 4.4-4.6 δ (2 H); multiplet 4.2 δ (3 H); singlet 2.4 δ (3 H).

25

#### INTERMEDIATE 12

##### Toluene-4-sulfonic acid 7-nitro-8-(2-nitro-but-1-enyl)-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester

30

To a solution of 1.0 g (2.45 mmole) of (2R)-(8-formyl-7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl 4-methylbenzenesulfonate in 15 mL of acetic acid was added 0.87 mL (9.8 mmole) of nitropropane and 0.38 g (4.9 mmole) of ammonium acetate and the mixture was heated at 80°C under nitrogen for 6 hours. After the mixture cooled, the solvent was removed in vacuum and replaced with 200 mL of ethyl



acetate. The solution was washed with 200 mL of water and the aqueous wash was back-extracted with an additional 200 mL of ethyl acetate. The combined organics were washed with 200 mL each of saturated aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuum to an oily yellow solid. Column chromatography on silica gel with 1:1 hexane/ethyl acetate as eluant gave 0.70 g of the (R)-enantiomer of the title compound as a yellow solid. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): doublet 7.8 δ (2 H); doublet 7.75 δ (1 H); doublet 7.4 δ (2 H); doublet 7.03 δ (1 H); singlet 5.3 δ (1 H); multiplet 4.45 δ (1 H); multiplet 4.4 δ (1 H); multiplet 4.21 δ (3 H); singlet 2.45 δ (3 H); quartet 2.4 δ (2 H); triplet 1.0 δ (3 H).

10

### INTERMEDIATE 13

#### [8-Ethyl-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol-2-yl)methyl 4-methylbenzenesulfonate

0.70 g (1.5 mmole) of toluene-4-sulfonic acid (2R)-7-nitro-8-(2-nitro-but-1-enyl)-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester was dissolved in 100 mL of ethyl acetate and 0.10 g of platinum oxide added. The mixture was treated with 45 psi of hydrogen on a Parr hydrogenation apparatus for 5 hours. The mixture was then filtered through celite and concentrated in vacuum. The residue was column chromatographed on silica gel with 1:1 ethyl acetate/hexane to give 0.52 g of the (R)-enantiomer of the title compound as a yellow oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): doublet 7.8 δ (2 H); doublet 7.3 δ (2 H); doublet 6.76 δ (1 H); doublet 6.64 δ (1 H); singlet 6.16 δ (1 H); multiplet 4.5 δ (1 H); multiplet 4.3 δ (3 H); quartet 4.1 δ (1 H); quartet 2.75 δ (2 H); singlet 2.5 δ (3 H); triplet 1.3 δ (3 H).

25

### EXAMPLE 4

#### 8-Ethyl-2-[(4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole

A solution of 0.52 g (1.3 mmole) of [(2R)-8-ethyl-2,3-dihydro-7H-[1,4]-dioxino[2,3-e]indol-2-yl)methyl 4-methylbenzenesulfonate and 0.80 g (4.1 mmole) of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole in 20 mL of DMSO was heated at 65°C for 3 hours. The mixture was diluted with 300 mL of ethyl acetate, washed with 200 ml

portions of saturated aqueous sodium bicarbonate and saturated brine, dried over magnesium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with 0-2% methanol in methylene chloride as eluant. The product fractions were combined and concentrated in vacuum, and the residue  
5 triturated with ether/hexane (1:1) to give 0.11 g of the (S)-enantiomer of the title compound as a yellow solid hydrate, m.p. 175-177°C.

Elemental Analysis for:  $C_{26}H_{27}N_3O_2 \cdot H_2O$

Calc'd: C, 72.37; H, 6.77; N, 9.74

Found: C, 72.67; H, 6.63; N, 9.62

10

#### EXAMPLE 5

#### 8-Ethyl-2-[(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl-1,2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole

15 A solution of 0.41 g (0.11 mmole) of [(2R)-8-ethyl-2,3-dihydro-7H-[1,4]-dioxino[2,3-e]indol-2-yl]methyl 4-methylbenzenesulfonate and 0.71 g (3.3 mmole) of 5-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole in 25 mL of DMSO were heated at 75-80°C for 4 hours. The mixture was diluted with 300 mL of ethyl acetate, washed with 200 ml portions of saturated aqueous sodium bicarbonate and saturated brine,  
20 dried over magnesium sulfate, filtered and concentrated in vacuum. The residue was column chromatographed on silica gel with 0-2% methanol in methylene chloride as eluant. The product fractions were combined and concentrated in vacuum, and the residue triturated with ether/hexane (1:1) to give 0.090 g of the (S)-enantiomer of the title compound as a yellow solid hydrate, m.p. 81-82°C.

25 Elemental Analysis for:  $C_{26}H_{26}FN_3O_2 \cdot H_2O$


Calc'd: C, 69.47; H, 6.28; N, 9.35

Found: C, 69.72; H, 6.30; N, 9.25

CLAIMS

What is claimed is:

- 5 (1) A compound of formula I:



wherein

- 10 R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>7</sup> are, independently, hydrogen, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, or alkanesulfonamido of 1 to 6 carbon atoms;

- 15 R<sup>2</sup> is hydrogen, halogen, alkyl of 1 to 6 carbon atoms or trifluoromethyl;  
R<sup>6</sup> is hydrogen or alkyl of 1 to 6 carbon atoms;  
Z is CR<sup>7</sup> or N;

or a pharmaceutically acceptable salt thereof.

- 20 (2) A compound according to Claim 1 wherein R<sup>1</sup> is hydrogen, halogen, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms.

- (3) A compound according to Claim 1 or Claim 2 wherein R<sup>2</sup> is hydrogen, trifluoromethyl or alkyl of 1 to 6 carbon atoms.

25

- (4) A compound according to Claim 1 or Claim 2 wherein R<sup>2</sup> is hydrogen or lower alkyl.


- (5) A compound according to any one of Claims 1 to 4 wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halogen, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, and alkoxy of 1 to 6 carbon atoms.
- 5 (6) A compound according to any one of Claims 1 to 4 wherein, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halo and cyano.
- (7) A compound according to any one of Claims 1 to 6 wherein R<sup>6</sup> is hydrogen.
- 10 (8) A compound according to any one of Claims 1 to 7 wherein Z is CR<sup>7</sup> and R<sup>7</sup> is hydrogen, halo or cyano.
- (9) A compound of Claim 1 in which R<sup>1</sup> is hydrogen, halogen, cyano, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms;  
15 and R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halo, cyano, carboxamido, alkyl of one to six carbon atoms, and alkoxy of one to six carbon atoms.
- (10) A compound of Claim 1 in which R<sup>1</sup> is hydrogen, halo, cyano, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms, R<sup>2</sup> is hydrogen,  
20 trifluoromethyl or alkyl of one to six carbon atoms, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen, halo and cyano, R<sup>6</sup> is hydrogen, Z is CR<sup>7</sup> and R<sup>7</sup> is hydrogen, halo or cyano.
- (11) A compound of Claim 1 wherein R<sup>1</sup> is hydrogen, R<sup>2</sup> is hydrogen or lower alkyl,  
25 R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are independently selected from hydrogen or halogen, R<sup>6</sup> is hydrogen, Z is CR<sup>7</sup> and R<sup>7</sup> is hydrogen or halogen.
- (12) A compound of Claim 1 which is 2-[(4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-8-methyl-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole or a pharmaceutically  
30 acceptable salt thereof.
- (13) A compound of Claim 1 which is 2-[(4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole or a pharmaceutically acceptable salt thereof.

35


- (14) A compound of Claim 1 which is 2-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl]-2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole or a pharmaceutically acceptable salt thereof.
- 5
- (15) A compound of Claim 1 which is 8-ethyl-2-[[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)nyl]methyl]-2,3-dihydro-7H-[1,4]dioxino[2,7-e]indole or a pharmaceutically acceptable salt thereof.
- 10
- (16) A compound of Claim 1 which is 8-ethyl-2-[[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl]-2,3-dihydro-7H-[1,4]dioxino[2,7-e]indole or a pharmaceutically acceptable salt thereof.
- 15
- (17) A method of treating a subject suffering from a condition selected from the group consisting of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, which comprises providing to the subject suffering from said condition, a
- 20
- therapeutically effective amount of a compound of formula I as claimed in any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.
- (18) The method of Claim 17 wherein the condition is selected from the group consisting of obsessive compulsive disorder, panic attacks, generalized anxiety
- 25
- disorder, and social anxiety disorder.
- (19) The method of Claim 18 wherein the subject is a human.
- (20) A pharmaceutical composition comprising a compound of formula I as claimed
- 30
- in any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

(21) A process for preparing a compound according to claim 1 which comprises one of the following:

a) reacting a compound of formula



5 wherein R<sup>1</sup> and R<sup>2</sup> are as defined in claim 1 and x is a leaving group, e.g. a halogen or an organic sulphonyloxy group such as methane- or toluene-, with a compound of formula (III):



10 wherein Z, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in Claim 1 to give a compound of formula (I);  
or  
(b) converting a basic compound of formula (I) to a pharmaceutically acceptable acid addition salt thereof;  
or  
15 (c) resolving an isomeric mixture of compounds of formula (I) to isolate an enantiomer of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number  
**WO 02/088146 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 519/00**,  
491/04, A61K 31/407, A61P 25/00 // (C07D 491/04,  
319:00, 209:00) (C07D 519/00, 491:00, 471:00)

(21) International Application Number: PCT/US02/13118

(22) International Filing Date: 25 April 2002 (25.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/286,575 26 April 2001 (26.04.2001) US

(71) Applicant: **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(88) Date of publication of the international search report:  
13 February 2003

(72) Inventors: **STACK, Gary, Paul**; 525 Brookfield Lane, Ambler, PA 19002 (US). **TRAN, Megan**; Apt. 3G, 82 Clinton Street, Hoboken, NJ 07030 (US). **BRAVO, Byron, Abel**; Apartment H11, 201 Chariot Lane, Eagleville, PA 19403 (US).

(74) Agents: **BARRETT, Rebecca, R.**; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 et al. (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOX-INO[2,3-e]INDOLE



(1)

(57) Abstract: Compounds of the formula (I) are useful in the treatment of central nervous system disorders including depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, sexual dysfunction, eating disorders and addictive disorders caused by ethanol or cocaine abuse.

WO 02/088146 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13118

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D519/00 C07D491/04 A61K31/407 A61P25/00  
 //(C07D491/04,319:00,209:00),(C07D519/00,491:00,471:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 91 13872 A (UPJOHN CO) 19 September 1991 (1991-09-19) claims	1-21
A	ENNIS M D ET AL: "NOVEL INDOLODIOXANES WITH ANTIHYPERTENSIVE EFFECTS: POTENT LIGANDS FOR THE 5-HT1A RECEPTOR" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 16, 7 August 1992 (1992-08-07), pages 3058-3066, XP000608326 ISSN: 0022-2623 the whole document	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

22 October 2002

Date of mailing of the international search report

31/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Chouly, J



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/13118

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 23485 A (KNOLL AG ;BIRCH ALAN MARTIN (GB); BRADLEY PAUL ANTHONY (GB); GILL) 3 July 1997 (1997-07-03) claims ---	1-21
A	WO 98 40386 A (KNOLL AG ;BIRCH ALAN MARTIN (GB); BRADLEY PAUL ANTHONY (GB)) 17 September 1998 (1998-09-17) claims -----	1-21

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/13118

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 17-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/13118

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9113872	A	19-09-1991	AU 639536 B2	29-07-1993
			AU 7303091 A	10-10-1991
			CA 2075057 A1	16-09-1991
			EP 0594593 A1	04-05-1994
			WO 9113872 A1	19-09-1991
			US 5302599 A	12-04-1994
WO 9723485	A	03-07-1997	AU 1195897 A	17-07-1997
			DE 69619704 D1	11-04-2002
			WO 9723485 A1	03-07-1997
			EP 0876372 A1	11-11-1998
			JP 2000502662 T	07-03-2000
			US 6107310 A	22-08-2000
WO 9840386	A	17-09-1998	AU 6721598 A	29-09-1998
			WO 9840386 A1	17-09-1998
			EP 0966470 A1	29-12-1999
			JP 2001515485 T	18-09-2001
			US 6201004 B1	13-03-2001
			US 2001008903 A1	19-07-2001

THIS PAGE BLANK (USPTO)